Medication info

Kwangdong Metformin-Citagliptin Tablet 50/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride with Colloidal Anhydrous Silica›1010mg / 1 tablet
Manufacturer / importer
Kwangdong Pharmaceutical Co., Ltd.
Appearance
Brown oval film-coated tablet engraved with 751 on one side
Packaging
30 tablets/box [(10 tablets/PTP x 3)]
Approval status
Active

MFDS item code 202200318 · Approved 2022.01.19

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
In antidiabetic therapy, the dose of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medication is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medication should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for patients who do not achieve adequate glycemic control with sitagliptin monotherapy, the initial dose is 1 tablet of this medication 50/500 mg twice daily. The dose may be increased to 1 tablet of this medication 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medication is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medication may start at their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should take into account the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medication because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication should be discontinued immediately.

Ingredients

Manufacturer
Kwangdong Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Difficulty in blood glucose control in patients with type 2 diabetes
View approved original text

This medication helps to complement dietary and exercise therapy for blood glucose control in patients with type 2 diabetes. It is used as monotherapy for those beginning treatment for diabetes and can also be used when blood glucose control is insufficient after monotherapy. This medication serves as an alternative when blood glucose control is difficult with monotherapy of either Metformin or Citagliptin. Additionally, it can be combined with Metformin and sulfonylureas or thiazolidinediones when blood glucose control is inadequate. When insulin is used in combination with Metformin and blood glucose control is still challenging, this medication can be added to the treatment regimen. Overall, this medication is effective in improving blood glucose management in various treatment stages and combination scenarios.

How to take

Adult dose

In antidiabetic therapy, the dose of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medication is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medication should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for patients who do not achieve adequate glycemic control with sitagliptin monotherapy, the initial dose is 1 tablet of this medication 50/500 mg twice daily. The dose may be increased to 1 tablet of this medication 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medication is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medication may start at their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should take into account the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medication because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication should be discontinued immediately.

Precautions

This medication contains Citagliptin and Metformin hydrochloride and is used for diabetes treatment. First, serious allergic reactions may occur while taking this medication, so if there are symptoms such as rash, hives, difficulty breathing, or swelling of the face or neck, stop taking the medication immediately and consult a doctor. There is also a risk of pancreatitis, which is inflammation of the pancreas, so if abdominal pain, vomiting, or severe abdominal pain occurs, inform your healthcare provider immediately. This medication should not be administered to patients with poor kidney function, nor should it be taken in cases of rapidly deteriorating heart function, severe infections, or dehydration. Before and after receiving iodinated contrast agents, discontinue this medication 48 hours prior, as it may impose a strain on the kidneys, and resume only after kidney function is confirmed to be normal. It is safest for pregnant women, women who may become pregnant, and nursing mothers not to take this medication. Patients should be cautious about hypoglycemic symptoms while on this medication, especially if taking other hypoglycemic agents or insulin, as this may increase the risk of hypoglycemia. Additionally, there is a rare but serious metabolic disorder known as lactic acidosis that may occur due to Metformin, so if symptoms such as severe fatigue, muscle pain, difficulty breathing, or abdominal pain appear, inform your healthcare provider immediately. Elderly patients or those with reduced kidney function should take extra caution and undergo regular kidney function tests. It is advisable to avoid excessive alcohol consumption during treatment, and the medication may need to be temporarily discontinued around surgery. Finally, if blisters appear on the skin or if severe joint pain occurs during treatment, patients should inform their doctor immediately. The dosage and duration of this medication may vary depending on the patient's condition, so it is essential to take it strictly according to the doctor's instructions and to undergo regular check-ups.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory infection
  • headache
  • nausea
Show 22 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and disabling arthralgia
  • vesicular pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • dermatitis
  • loss of appetite
  • weight loss
  • dyspnea
  • unstable angina
  • dizziness
  • acute renal failure
  • decreased appetite
  • gastrointestinal disturbance
  • itching

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture and kept at room temperature between 1 degree Celsius and 30 degrees Celsius. Proper storage helps maintain the effectiveness of the medication for a longer duration.

Appearance and packaging

Appearance

Brown oval film-coated tablet engraved with 751 on one side

Package unit

30 tablets/box [(10 tablets/PTP x 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.